Potent Hypolipidemic Activity of Mimetic Amides of Fibrates Based on the 2-Methoxy-4-(2-propenyl)phenoxyacetic Scaffold

Drug Development Research

Volumn 61, Issue 1, 2004, Pages 19-36

  Hernández, Dolores ^a   Bernal, Pablo ^a   Cruz, Adriana ^a   Garciafigueroa, Yesica ^a   Garduño, Leticia ^a   Salazar, María ^a   Díaz, Francisco ^a   Chamorro, Germán ^a   Tamariz, Joaquín ^a  

^a INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

Author keywords

asarone; Fibrate bioisosteres; Hypocholesterolemia; Phenoxyacetamide pharmacophores

Indexed keywords

1 [3 [2 METHOXY 4 (2 PROPENYL)PHENOXY]PROPYL] 4 (3 CHLOROPHENYL)PIPERAZINE; 2 [2 METHOXU 4 (2 PROPENYL)PHENOXY] N (2 CHLOROETHYL)ACETAMIDE; 2 [2 METHOXY 4 (1 PROPENYL)PHENOXY]ETHYLAMINE; 2 [2 METHOXY 4 (2 PROPENYL)PHENOXY] 1 (MORPHOLIN 4 YL)ETHAN 1 ONE; 2 [2 METHOXY 4 (2 PROPENYL)PHENOXY] 1 [4 (3 CHLOROPHENYL)PIPERAZIN 1 YL]ETHAN 1 ONE; 2 [2 METHOXY 4 (2 PROPENYL)PHENOXY] N (1 PHENYLETHYL)ACETAMIDE; 2 [2 METHOXY 4 (2 PROPENYL)PHENOXY] N (2 MORPHOLINYL 4 ETHYL)ACETAMIDE; 2 [2 METHOXY 4 (2 PROPENYL)PHENOXY] N (2 PHENOXYETHYL)ACETAMIDE; 2 [2 METHOXY 4 (2 PROPENYL)PHENOXY] N [2 [2 METHOXY 4 (2 PROPENYL)PHENOXY]ETHYL]ACETAMIDE; 2 [2 METHOXY 4 (2 PROPENYL)PHENOXY] N TERT BUTYLACETAMIDE; 2 [2 METHOXY 4 (2 PROPENYL)PHENOXY] N,N DIETHYLACETAMIDE; 2 [2 METHOXY 4 (2 PROPENYL)PHENOXY] N,N DIMETHYLACETAMIDE; 2 [2 METHOXY 4 (2 PROPENYL)PHENOXY]ACETAMIDE; 2 [2 METHOXY 4 (2 PROPENYL)PHENOXY]ETHYLAMINE; [2 [2 METHOXY 4 (2 PROPENYL)PHENOXY]ETHYL]DIMETHYLAMINE; ANTILIPEMIC AGENT; AROMATIC AMIDE; BEZAFIBRATE; CHLORINE; CLOFIBRATE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; N [2 [2 METHOXY 4 (1 PROPENYL)PHENOXY]ETHYL] 3 PHENOXYPROPIONAMIDE; N [2 [2 METHOXY 4 (1 PROPENYL)PHENOXY]ETHYL] 4 CHLOROBENZAMIDE; N [2 [2 METHOXY 4 (2 PROPENYL)PHENOXY]ETHYL] 3 CHLOROBENZAMIDE; N [2 [2 METHOXY 4 (2 PROPENYL)PHENOXY]ETHYL] 3 PHENOXYPROPIONAMIDE; PHENOXYACETIC ACID DERIVATIVE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG DETERMINATION; DRUG EFFECT; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; MALE; MOUSE; NONHUMAN; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0346727388     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.10333     Document Type: Article

References (31)

1. Aston KW, Henke SL, Modak AS, Riley DP, Sample KR, Weiss RH, Neumann WL. 1994. Asymmetric synthesis of highly functionalized polyazamacrocycles via reduction of cyclic peptide precursors. Tetrahedron Lett 35:3687-3690.
2. Burgess LE, Meyers AI. 1992. A simple asymmetric synthesis of 2-substituted pyrrolidines and 5-substituted pyrrolidinones. J Org Chem 57:1656-1662.
3. Chamorro G, Salazar M, Salazar S, Mendoza T. 1993. Farmacología y toxicologia de Guatteria ganneri. Rev Inv Clin 45:597-604.
4. Chamorro G, Garduño L, Sánchez A, Labarrios F, Salazar M, Martínez E, Díaz F, Tamariz, J. 1998. Hypolipidaemic activity of dimethoxy unconjugated propenyl side-chain analogs of α-asarone in mice. Drug Dev Res 43:105-108.
5. Cruz A, Garduño L, Salazar M, Martínez E, Díaz F, Chamorro G, Tamariz J. 2001a. High hypolipidemic activity of saturated side-chain α-asarone analogs. Med Chem Res 10:587-595.
6. Cruz A, Garduño L, Salazar M, Martínez E, Jiménez-Vázquez, HA, Díaz F, Chamorro G, Tamariz, J. 2001b. Synthesis and hypolipidemic activity of modified side chain α-asarone homologues. Arzneimittelforschung 51:535-544.
7. Danishefsky, S, Hirama M, Gombatz K, Harayama T, Berman E, Schuda PF. 1979. Total synthesis of d1-pentalenolactone. J Am Chem Soc 101:7020-7031.
8. Díaz F, Muñoz H, Labarrios F, Chamorro G, Salazar M, Morelos ME, Tamariz J. 1993. Synthesis and hypolipidemic activity of some α-asarone analogs. Med Chem Res 3:101-109.
9. Ebdrup S, Petterson I, Rasmussen HB, Deussen H-J, Jensen AF, Mortensen SB, Fleckner J, Pridal L, Nygaard L, Sanerberg P. 2003. Synthesis and biological and structural characterization of the drug-acting peroxisome proliferator-activated receptor α/γ agonist ragaglitazar. J Med Chem 46:1306-1317.
10. Faergeman O. 2000. Hypertriglyceridemia and the fibrate trials. Curr Opin Lipidol 11:609-614.
11. Fox DNA, Lathbury, D, Mahon MF, Molloy KC, Gallagher T. 1991. Enantioselective synthesis of pumiliotoxin 251D. A strategy employing an allene-based electrophile-mediated cyclization. J Am Chem Soc 113:2652-2656.
12. Fruchart JC, Duriez P, Staels B. 1999. Molecular mechanisms of action of the fibrates. J Soc Biol 193:67-75.
13. García Ruano JL, Martínez MC, Rodríguez JH, Olefirowicz EM, Eliel EL. 1992. Synthesis of 2-phenyl-, 3-phenyl, cis-2,3-diphenyl-, and trans-2,3-diphenyl-1,4-thiazanes and derivatives (N-methyl, N-alkoxycarbonyl, S-oxides, and S,S-dioxides). J Org Chem 57:4215-4224.
14. Garduño L, Salazar M, Salazar S, Morelos ME, Labarrios F, Tamariz J, Chamorro GA. 1997. Hypolipidemic activity of α-asarone in mice. J Ethnopharmacol 55:161-163.
15. Geigy A-G Jr. 1958. British patent 792,490. Chem Abstr 52:20057.
16. Hackling A, Stark H. 2002. Dopamine D receptor ligands with antagonist properties. ChemBioChem 3:946-961.
17. Jensen NP, Ager AL, Bliss RA, Canfield CJ, Kotecka BM, Rieckmann KH, Terpinski J, Jacobus DP. 2001. Phenoxypropoxybiguanides, prodrugs of DHFR-inhibiting diaminotriazine antimalarials. J Med Chem 44:3925-3931.
18. Jones BP, Porter AN. 1999. 2-Aroylbenzoyl serine proteoses: Photoreversible inhibition or photoaffinity labeling? J Am Chem Soc 121:2753-2761.
19. Kim Y-W, Mobley JA, Brueggemeier RW. 2003. Synthesis and estrogen receptor binding affinities of 7-hydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-ones containing a basic side chain. Bioorg Med Chem Lett 13:1475-1478.
20. Klansner YS, Bodansky M. 1972. Coupling reagents in peptide synthesis. Synthesis 453-463.
21. Kreeman V, Shottova N, Walterová D, Ulrichová J, Simánek V. 1998. Silymarin inhibits the development of diet-induced hypercholesterolemia in rats. Planta Med 64:138-142.
22. Labarrios F, Garduño L, Vidal MR, García R, Salazar M, Martínez E, Díaz F, Chamorro G, Tamariz J. 1999. Synthesis and hypolipidaemic activity of a series of α-asarone analogues related to clofibrate in mice. J Pharm Pharmacol 51:1-7.
23. Lehman JM, Moore LB, Smith Oliver TA. 1995. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 270:12053-12956.
24. Loveday C. 1971. Comparison of the hyperalgesic activity of some intravenous anesthetic in mice. Arch Int Pharmacodyn Ther 1992:271-278.
25. Mickelson JW, Belonga KL, Jacobsen EJ. 1995. Asymmetric synthesis of 2,6-methylated piperazines. J Org Chem 60: 4177-4183.
26. Siemoneit KD, Zipf HF, Dittmann EC. 1966. Endoanesthetic and hypnotic-narcotic effect of 2-methoxy-4-allylphenoxyacetic acid diethylamide (G 29505) and related phenolic derivatives. Arch Int Pharmacodyn Ther 164:30-46.
27. Smith MB, March J. 2001. March's advanced organic chemistry. New York: John Wiley & Sons. p 506-507.
28. Sridhar GR. 2003. Peroxisome proliferator-activated receptors as molecular target for drug therapy. J Assoc Physicians India 51: 49-52.
29. Tallarida RJ, Murray RB. 1987. Manual of pharmacological calculations. New York: Springer Verlag. p 131.
30. - in acidic dimethyl sulfoxide. J Org Chem 46:2579-2581.
31. Watts GF, Dimmitt SB. 1999. Fibrates, dyslipoproteinaemia and cardiovascular disease. Curr Opin Lipidol 10:561-574.